Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Clinical and Translational Medicine|January 24, 2024
Seize the engine: Emerging cell cycle targets in breast cancerJesús Fuentes-Antrás, Philippe L Bedard, David W CesconTrends in Cancer|February 6, 2023
Antibody-drug conjugates: in search of partners of choiceJesús Fuentes-Antrás, Sofia Genta, Abi Vijenthira, et al.Immunology Letters|January 8, 2021
Immunodeficiency and thymoma in Good syndrome: Two sides of the same coinKissy Guevara-Hoyer, Jesús Fuentes-Antrás, Joaquín Calatayud Gastardi, et al.Cardiovascular Diabetology|April 10, 2015
Targeting metabolic disturbance in the diabetic heartJesús Fuentes-Antrás, Belén Picatoste, Elisa Ramírez, et al.Hematology/Oncology and Stem Cell Therapy|May 23, 2020
Fatal Autoimmune Storm After a Single Cycle of Anti-PD-1 Therapy: A Case of Lethal Toxicity but Pathological Complete Response in Metastatic Lung AdenocarcinomaJesús Fuentes-Antrás, Paloma Peinado, Kissy Guevara-Hoyer, et al.Frontiers in Oncology|November 5, 2019
Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-AnalysisRamy R Saleh, Paloma Peinado, Jesús Fuentes-Antrás, et al.Cancer Treatment Reviews|June 8, 2019
Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysisRamy R Saleh, Jesús Fuentes Antrás, Paloma Peinado, et al.The New Microbiologica|April 18, 2019
Acute Community-Acquired Bacterial Meningitis: Update on Clinical Presentation and Prognostic factorsJesús Fuentes-Antrás, Miguel Ramírez-Torres, Eduardo Osorio-Martínez, et al.Breast (Edinburgh, Scotland)|October 23, 2020
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemiaJesús Fuentes-Antrás, Alicia de Luna, Alfonso López de Sá, et al.Development (Cambridge, England)|July 12, 2017
Multiple modes of Lrp4 function in modulation of Wnt/β-catenin signaling during tooth developmentYoungwook Ahn, Carrie Sims, Megan J Murray, et al.Pageof 3